RE: Question for the experts8 Apr 2023 12:44
I've been looking at Intensity Therapeutics
INT230-6 recently, a clinical-stage biotechnology company focused on the discovery and development of proprietary, first-in-class immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, nearing completion of phase 2 study.phase 3 to conclude 2h 2023.
Yet to ipo but talks are on going possibly this year. 8% owned interest by prtg.
Is this the nearest direct threat to avacta and chemotherapy?
It would be interesting to know people's thoughts.
Another query is why haven't they had a buyout deal at there stage of study when working so closely with merck& Bristol-Myers Squibb.
If speculation is always made about us having one near term?
Happy eater everybody